Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Aug;20(8):926-8.
doi: 10.1016/j.parkreldis.2014.04.003. Epub 2014 Apr 14.

Cardiac sympathetic denervation without Lewy bodies in a case of multiple system atrophy

Affiliations
Case Reports

Cardiac sympathetic denervation without Lewy bodies in a case of multiple system atrophy

G A Cook et al. Parkinsonism Relat Disord. 2014 Aug.
No abstract available

Keywords: Alpha-synuclein; Catecholaldehyde; DOPAL; MSA; Multiple system atrophy; Parkinson disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
18F-DOPA (top and blow-up in middle) and 18F-dopamine (bottom) PET scans in control subjects (left) and in the current patient with MSA (right). There is neuroimaging evidence for decreased, distorted putamen 18F-DOPA-derived radioactivity and markedly decreased cardiac sympathetic innervation.

Similar articles

Cited by

References

    1. Goldstein DS, Orimo S. Cardiac sympathetic neuroimaging: summary of the First International Symposium. Clin Auton Res. 2009;19:133–6. - PMC - PubMed
    1. Raffel DM, Koeppe RA, Little R, Wang CN, Liu S, Junck L, et al. PET measurement of cardiac and nigrostriatal denervation in parkinsonian syndromes. J Nucl Med. 2006;47:1769–77. - PubMed
    1. Orimo S, Kanazawa T, Nakamura A, Uchihara T, Mori F, Kakita A, et al. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol Berl. 2007;113:81–6. - PubMed
    1. Goldstein DS, Holmes C, Sharabi Y. Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson’s disease and other synucleinopathies. Brain. 2012;135:1900–13. - PMC - PubMed
    1. Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, et al. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. J Neurochem. 2013;126:591–603. - PMC - PubMed

LinkOut - more resources